Literature DB >> 9010283

Purification and characterization of the NS3 serine protease domain of hepatitis C virus expressed in Saccharomyces cerevisiae.

W Markland1, R A Petrillo, M Fitzgibbon, T Fox, R McCarrick, T McQuaid, J R Fulghum, W Chen, M A Fleming, J A Thomson, S P Chambers.   

Abstract

cDNA encoding the putative core of the hepatitis C virus NS3 serine protease domain (residues 1-181 of NS3; NS3 (181)) was expressed as an N-terminally (His)6-tagged fusion protein in Saccharomyces cerevisiae. NS3 (181) protease activity was found in soluble cell lysates, and the N-terminal metal-chelating domain facilitated the efficient purification of active enzyme, using immobilized metal affinity chromatography. The purified NS3(181), protease activity was characterized by assaying the trans-cleavage of in vitro transcription-translation generated substrates, and subsequently a previously unobserved cleavage site within the NS5A region was identified. The inhibitory effect of known protease inhibitors was also examined. It is hoped that availability of this method for the expression and purification of the NS3(181) protease will facilitate the development of anti-hepatitis C therapies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010283     DOI: 10.1099/0022-1317-78-1-39

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Polynucleotide modulation of the protease, nucleoside triphosphatase, and helicase activities of a hepatitis C virus NS3-NS4A complex isolated from transfected COS cells.

Authors:  K A Morgenstern; J A Landro; K Hsiao; C Lin; Y Gu; M S Su; J A Thomson
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

2.  Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Authors:  Robert B Perni; Susan J Almquist; Randal A Byrn; Gurudatt Chandorkar; Pravin R Chaturvedi; Lawrence F Courtney; Caroline J Decker; Kirk Dinehart; Cynthia A Gates; Scott L Harbeson; Angela Heiser; Gururaj Kalkeri; Elaine Kolaczkowski; Kai Lin; Yu-Ping Luong; B Govinda Rao; William P Taylor; John A Thomson; Roger D Tung; Yunyi Wei; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

3.  Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients.

Authors:  K Nagayama; N Enomoto; N Izumi; M Kurosaki; Y Miyasaka; H Watanabe; J Itakura; C H Chen; J Tazawa; Y Hoshino; T Ikeda; F Marumo; C Sato
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

4.  Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase.

Authors:  Chen Zhang; Zhaohui Cai; Young-Chan Kim; Ranjith Kumar; Fenghua Yuan; Pei-Yong Shi; Cheng Kao; Guangxiang Luo
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses.

Authors:  Christoph Sarrazin; Eva Herrmann; Katharina Bruch; Stefan Zeuzem
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.